Ruilope L - Search Results

1

[2018 ESC/ESH Guidelines for the management of arterial hypertension].

Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I. Williams B, et al. Among authors: ruilope l. Kardiol Pol. 2019;77(2):71-159. doi: 10.5603/KP.2019.0018. Kardiol Pol. 2019. PMID: 30816983 Free article. Polish. No abstract available.

2

What have we learned from the HOT (Hypertension Optimal Treatment) study?

Ruilope LM, Hansson L, Zanchetti A. Ruilope LM, et al. Nephrol Dial Transplant. 1997 Oct;12(10):2047-8. doi: 10.1093/ndt/12.10.2047. Nephrol Dial Transplant. 1997. PMID: 9351060 No abstract available.

3

Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group.

Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R, Larochelle P, McInnes GT, Mallion JM, Ruilope L, Wedel H. Zanchetti A, et al. Among authors: ruilope l. J Hypertens. 2001 Jun;19(6):1149-59. doi: 10.1097/00004872-200106000-00021. J Hypertens. 2001. PMID: 11403365 Clinical Trial.

4

ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations?

Ruilope LM, Coca A, Volpe M, Waeber B. Ruilope LM, et al. Am J Hypertens. 2002 Apr;15(4 Pt 1):367-71. doi: 10.1016/s0895-7061(02)02258-6. Am J Hypertens. 2002. PMID: 11991225

5

Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?

Zanchetti A, Ruilope LM. Zanchetti A, et al. J Hypertens. 2002 Nov;20(11):2099-110. doi: 10.1097/00004872-200211000-00001. J Hypertens. 2002. PMID: 12409940 Review.

6

Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors.

Palmer CR, Brown MJ, Mancia G, Ruilope LM; INSIGHT Steering Committee. Palmer CR, et al. JAMA. 2003 Apr 23-30;289(16):2066-7; author reply 2069-70. doi: 10.1001/jama.289.16.2066-c. JAMA. 2003. PMID: 12709455 No abstract available.

7

Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study.

Aranda P, Ruilope LM, Calvo C, Luque M, Coca A, Gil de Miguel A. Aranda P, et al. Am J Hypertens. 2004 Feb;17(2):139-45. doi: 10.1016/j.amjhyper.2003.09.006. Am J Hypertens. 2004. PMID: 14751656 Clinical Trial.

8

On the importance of estimating renal function for cardiovascular risk assessment.

Segura J, Ruilope LM, Zanchetti A. Segura J, et al. J Hypertens. 2004 Sep;22(9):1635-9. doi: 10.1097/00004872-200409000-00001. J Hypertens. 2004. PMID: 15311085 Review.

9

Microalbuminuria as an intermediate endpoint in essential hypertension: evidence is coming.

Redon J, Ruilope LM. Redon J, et al. J Hypertens. 2004 Sep;22(9):1679-81. doi: 10.1097/00004872-200409000-00010. J Hypertens. 2004. PMID: 15311094 Review. No abstract available.

10

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.

Ruilope LM, Rosei EA, Bakris GL, Mancia G, Poulter NR, Taddei S, Unger T, Volpe M, Waeber B, Zannad F. Ruilope LM, et al. Blood Press. 2005;14(4):196-209. doi: 10.1080/08037050500230227. Blood Press. 2005. PMID: 16126553 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

886 results

Search Page

Filters